Ixekizumab (Anti-CTLA-8 / IL-17a)

Ixekizumab (Anti-CTLA-8 / IL-17a) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab has the potential to be used in research on plaque psoriasis. MW: 146.44 KD.
Supplier Selleck Chemicals
Product # A2862
Sku # A2862-1mg*5
Pricing 1mg*5, $970.00
Feedback